Sidra Medicine introduces Qatar’s first advanced gene-editing therapy for sickle cell disease and thalassemia

Sidra Medicine introduces Qatar’s advanced gene-editing therapy

Sidra Medicine, a member of Qatar Foundation, has been qualified by Vertex Pharmaceuticals as one of a limited number of hospitals in the world to administer Casgevy, a groundbreaking, one-time CRISPR/Cas9-based gene therapy treatment. Casgevy is now available in Qatar for patients aged 12 years and older, living with transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD). Prof. Ibrahim Janahi, Chief Medical Officer at…

Sidra Medicine introduces Qatar’s first advanced gene-editing therapy for sickle cell disease and thalassemia

First Patient Onboarded for Treatment